Back to search

Article

Single HER2-Positive Tumor Cells are Detected in Initially HER2-Negative Breast Carcinomas using the DEPArray™–HER2-FISH Workflow

2021-08-26

Abstract excerpt

<h4>Background: </h4> In breast cancer (BC), overexpression of HER2 on the primary tumor (PT) is determined by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to stratify samples as negative, equivocal and positive to identify patients (pts) for anti-HER2 therapy. CAP/ASCO guidelines recommend FISH for analyzing HER2/neu ( ERBB2 ) gene amplification and for resolving equivocal HER2 IHC resu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
12c1d232-98d0-5497-85c2-fcf7ca8a2a0b
DOI
10.21203/rs.3.rs-820771/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Single HER2-Positive Tumor Cells are Detected in Initially HER2-Negative Breast Carcinomas using the DEPArray™–HER2-FISH WorkflowDOI 10.21203/rs.3.rs-820771/v1
Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancersSemantic proximity
Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast CancerSemantic proximity
Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity
Comparison of the Mutation Profiles of Triple-Negative Breast Cancers and Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers at the T2N0-1M0 StageSemantic proximity
Deciphering HER2 Breast Cancer Disease: Biological and Clinical ImplicationsSemantic proximity
Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation PracticeSemantic proximity
Dissecting the biological heterogeneity of HER2-positive breast cancerSemantic proximity
Optimizing Detection of Circulating Tumor Cells in Breast Cancer: Unveiling New Markers for Clinical ApplicationsSemantic proximity
Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.Semantic proximity
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerSemantic proximity
Whole Genome Sequencing in single CTC improves clinical outcome in Her-2 negative breast cancer patientsSemantic proximity
HER2 in solid tumors: more than 10 years under the microscope; where are we now?Semantic proximity
Select a neighboring publication to make it the new centre.